Drugs / TNX-1300
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06045793 | Aug 2024 → Apr 2025 | cocaine abuse, cocaine intoxication | Tonix Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04996056 | Sep 2021 → Jun 2022 | cocaine intoxication | Tonix Pharmaceuticals, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-05-23 | Tonix Pharmaceuticals, Inc. | Regulatory Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication tonixpharma.com ↗
TNX-1300 is designated as a breakthrough therapy by the U.S. Food and Drug Administration (FDA). |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-08-20 | Tonix Pharmaceuticals, Inc. | Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication tonixpharma.com ↗ |
| 2022-08-02 | Tonix Pharmaceuticals, Inc. | Tonix Pharmaceuticals Receives Federal Grant from the National Institute on Drug Abuse (NIDA) to Advance Development of TNX-1300 as a Treatment for Cocaine Intoxication tonixpharma.com ↗ |
| 2022-06-27 | Tonix Pharmaceuticals, Inc. | Tonix Pharmaceuticals Announces Trial Design of New Phase 2 Clinical Study of TNX-1300 for Cocaine Intoxication tonixpharma.com ↗ |
| 2019-05-23 | Tonix Pharmaceuticals, Inc. | Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication tonixpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNX-1300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04996056 ↗ |
| Route | Intravenous | “TNX-1300 Intravenous injection 200 mg” NCT04996056 ↗ |